UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________

FORM 8-K

___________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

~~June~~July 229, 2026

Date of Report (Date of earliest event reported)

___________________________

CervoMed Inc.

(Exact name of registrant as specified in its charter)

___________________________

Delaware	001-37942	30-0645032
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

20 Park Plaza, Suite 424 Boston, Massachusetts		02116
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 744-4400

Not applicable

(Former name or former address, if changed since last report)

___________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CRVO		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1Item 7.01 Regulation FD Disclosure

~~Item~~On 7July 9, 2026, CervoMed Inc.01 (the “Company”) issued a press release announcing it has completed enrollment in the Company’s Phase 2a study of neflamapimod for the treatment of nonfluent variant primary progressive aphasia, a type of frontotemporal dementia (“FTD”). ~~Regulation~~A FDcopy ~~Disclosure~~of the press release is attached hereto as Exhibit 99. 1 and incorporated herein by reference.

OnThe ~~June~~information ~~22,~~in ~~2026,~~this ~~CervoMed~~Item ~~Inc~~7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “~~Company~~Exchange Act”), ~~issued~~or aotherwise ~~press~~subject ~~release~~to ~~announcing~~ the ~~closing~~liabilities of ~~its~~that ~~previously~~Section, ~~announced~~nor ~~registered~~shall ~~direct~~it ~~offering~~be ~~priced~~deemed ~~at-the-market~~incorporated ~~under~~by ~~Nasdaq~~reference ~~rules~~into ~~for~~any ~~the~~registration ~~purchase~~statement ~~and~~or ~~sale~~other filing under the Securities Act of 21933,~~500,000~~ ~~shares~~as ofamended, or the ~~Company’s~~Exchange ~~common~~Act, ~~stock~~except atas ashall ~~purchase~~be ~~price~~expressly ofset ~~$4.00~~forth ~~per~~by ~~share~~specific ofreference ~~common~~in ~~stock~~such ~~(the “Offering”)~~filing.

~~The~~Item ~~press release, which is furnished as Exhibit 99.1 to this Current Report on Form~~ 8~~-K, is incorporated herein by reference~~. ~~The information in or incorporated by reference into this Item 7.~~01 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The information set forth in the first and third paragraphs of, and under the headings “Recent Nature Neuroscience publication supports inhibition of p38α as potential therapeutic approach in FTD,” and “Interim results from the Phase 2a clinical trial to be presented at CTAD” in, the Company’s press release issued on July 9, 2026, is incorporated by reference into this Item 8.01. ~~Other~~of ~~Events~~this Current Report on Form 8-K.

OnItem ~~June~~9.01 Financial ~~22,~~Statements ~~2026,~~and ~~the Company closed the Offering.~~Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release., issued July 9, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CervoMed Inc.
Date: July 9, 2026	CervoMed Inc.
Date: June 22, 2026	By:	/s/ William Elder
	By:	/s/ William Elder
	Name:	~~Name:~~William Elder	~~William Elder~~
	Title:	~~Title:~~Chief Financial Officer & General Counsel	~~Chief Financial Officer & General Counsel~~

Filing Compare · CervoMed Inc.